<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531150</url>
  </required_header>
  <id_info>
    <org_study_id>INV101-CL-101</org_study_id>
    <nct_id>NCT04531150</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects</brief_title>
  <official_title>A Single Center, Phase I, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inversago Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inversago Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, randomized, double-blinded, placebo-controlled, single ascending-dose study&#xD;
      for the evaluation of the safety, tolerability, and PK following single oral doses of&#xD;
      INV-101.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Actual">May 16, 2021</completion_date>
  <primary_completion_date type="Actual">January 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Fully blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters - Maximum Concentration (Cmax)</measure>
    <time_frame>72 hours</time_frame>
    <description>Cmax following single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters - AUC</measure>
    <time_frame>72 hours</time_frame>
    <description>AUC following single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters - Half-live</measure>
    <time_frame>72 hours</time_frame>
    <description>Half-live following single dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>72 hours</time_frame>
    <description>Safety of INV-101 following single dose</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pharmacokinetic</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive either placebo or 20 mg INV-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive either placebo or 80 mg INV-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive either placebo or 160 mg INV-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive either placebo or 320 mg INV-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive either placebo or 500 mg INV-101</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INV-101</intervention_name>
    <description>Subjects will be randomized to receive INV-101 tablets</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be randomized to receive placebo tablets</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult male or female&#xD;
&#xD;
          -  Body mass index (BMI) within 18.5 kg/m2 to 30.0 kg/m2, inclusively; and body weight&#xD;
             â‰¥60 kg&#xD;
&#xD;
          -  Non- or ex-smoker&#xD;
&#xD;
          -  Have no clinically significant diseases captured in the medical history or evidence of&#xD;
             clinically significant findings on the physical examination (including vital signs)&#xD;
             and/or ECG, as determined by an investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female who is pregnant or lactating&#xD;
&#xD;
          -  Presence or history of significant gastrointestinal, liver or kidney disease, or&#xD;
             surgery that may affect drug bioavailability&#xD;
&#xD;
          -  History of significant cardiovascular, pulmonary, hematologic, neurological,&#xD;
             psychiatric, endocrine, immunologic or dermatologic disease&#xD;
&#xD;
          -  Presence of clinically significant ECG abnormalities at the screening visit, as&#xD;
             defined by medical judgment (maximum QTc of 450 for males and 470 for females)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn D Crater, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inversago Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altasciences</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

